Trials / Not Yet Recruiting

Not Yet RecruitingNCT07139548

A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes

A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Patients With Type 2 Diabetes

Status: Not Yet Recruiting
Phase: Phase 3
Study type: Interventional
Enrollment: 600 (estimated)

Sponsor: Guangdong Raynovent Biotech Co., Ltd · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

The reason for this study is to compare the effect of the study drug RAY1225 to semaglutide on blood sugar levels in participants with type 2 diabetes.

Conditions

T2DM

Interventions

Type	Name	Description
DRUG	RAY1225	Administered SC
DRUG	Semaglutide	Administered SC

Timeline

Start date: 2025-08-31
Primary completion: 2026-12-01
Completion: 2026-12-31
First posted: 2025-08-24
Last updated: 2025-08-24

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT07139548. Inclusion in this directory is not an endorsement.